Recipharm expands Italy plant

Recipharm

Recipharm, which picked up three plants two years ago with the buyout of Milan-based Corvette Pharmaceutical Services Group, is again expanding capabilities at one of them.  

The Sweden-based company says it will invest about $1.3 million (€1.2 million) to expand its small-scale GMP active pharmaceutical ingredient (API) development and manufacturing capabilities at the Paderno Dugnano facility.

Matteo Zacché, R&D manager for Recipharm in Paderno Dugnano, said that with the addition of the new laboratory, the company can now run up to six customer projects in parallel and handle maximum batch sizes of approximately 5 kg. Previously the lab could handle only about 1-kg batch sizes.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The facility also added new technology in flow chemistry, chromatography and other capabilities, he said. As a result of the expansion, the company also plans to increase the R&D staff to eight from the four employees currently working there.   

Recipharm paid about $164.5 million two years ago to buy Corvette from the Italian private equity group LBO Italia Investimenti. In addition to the plant in Paderno Dugnano, API and finished dose form development and manufacturing, it got a sterile injectables facility in Masate and a plant in Lainate that does bulk lyophilisation of sterile beta lactam antibiotics.

In August, Recipharm said it was investing about $4.2 million (€3.7 million) in Masate, to boost its vial filling capacity by about 20%.

Related Articles: 
Sweden's Recipharm moves on Italy with $160M deal for Corvette 
Recipharm expands Italian plant acquired last year

Read more on

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.